新型冠状病毒（SARS-CoV-2）对血液安全的影响*

doi:10.3969/j.issn.1671-2587.2020.03.003

临床输血与检验 ›› 2020, Vol. 22 ›› Issue (3): 232-235.DOI: 10.3969/j.issn.1671-2587.2020.03.003

• 新型冠状病毒肺炎专题（一） • 上一篇下一篇

新型冠状病毒（SARS-CoV-2）对血液安全的影响^*

严珺, 尹文, 张侃

710032 空军军医大学西京医院（严珺,尹文）;
武汉火神山医院医务部（张侃）

收稿日期:2020-03-09 出版日期:2020-06-20 发布日期:2020-06-13
通讯作者: 张侃,男,副教授,主要从事医院管理和输血安全研究,（E-mail）zhangkan2009@fmmu.edu.cn。
作者简介:严珺（1988-）,女,陕西渭南人,主管检验技师,硕士,主要从事血液病原生物检测工作,（E-mail）1174767049@qq.com。
基金资助:
*本课题受军事医学创新工程专项（20WQ016）资助

Impact of SARS-CoV-2 on Blood Safety

YAN Jun, YIN Wen, ZHANG Kan

Department of Blood Transfusion, Xijing Hospital of Air Force Military Medical University, Xi'an 710032

Received:2020-03-09 Online:2020-06-20 Published:2020-06-13

摘要/Abstract

摘要： 自2019年底至结稿,新型冠状病毒（SARS-CoV-2）在我国乃至全球持续蔓延,已成为全球地区重大的公共卫生威胁。目前科学家们已对SARS-CoV-2有了初步的了解,在对其传播途径的研究中发现,SARS-CoV-2具有潜伏期较长、无症状感染者较多的特点,这无疑是对当前血液安全的重大挑战。对于SARS-CoV-2能否经输血传播?如何保障疫情防控期间临床用血安全?如何降低新型冠状病毒经输血传播的风险?这些都是采供血机构关心和首要面对的问题。对比同为冠状病毒感染的严重急性呼吸道综合症（SARS）及中东呼吸综合症（MERS）有关血液安全的研究发现,并未发生过任何经呼吸道传播病毒经输血传播的报导,因此目前认为SARS-CoV-2能够经输血传播的风险仍是理论上的。但在疫情全面爆发的特殊时期,采供血机构可以自愿选择干预措施,最大限度的降低SARS-CoV-2经输血传播的风险,消除疫情期间人们对于血液安全的恐慌,保障临床用血安全。

关键词: 新型冠状病毒, 严重急性呼吸道综合症冠状病毒, 中东呼吸综合症冠状病毒, 血液安全

Abstract: Since the novel coronavirus (SARS-CoV-2) broke out in China at the end of 2019 and has been going around the world, it has become a global new public health threat. Scientists have had a preliminary understanding of the new coronavirus, and the research on the transmission route is getting deeper and deeper. It has been noted that SARS-CoV-2 has a long incubation period and a large number of asymptomatic infections, which is undoubtedly a major challenge to current blood safety. Is there any possibility that SARS-CoV-2 can be transmitted through blood transfusion? How do we ensure the safety of transfusion in clinical during epidemic prevention and reduce the risks of transmission of SARS-CoV-2 through blood transfusion? These are the major problems that the blood collection and supply agencies care about. As there has never been reported that respiratory borne virus can be transmitted through blood products, the risk that SARS-CoV-2 can be transmitted via blood transfusion is currently considered theoretically, based on the studies on acute respiratory syndrome (SARS) and middle East respiratory syndrome (MERS), both of which are caused by coronavirus infection as well. During the special period of time, the blood collection and supply institutions can take actions voluntarily to conduct intervention measures to minimize virus transmission through blood transfusion and eliminate people's panic on blood safety.

Key words: SARS-CoV-2, SARS-CoV, MERS-CoV, Blood safety

中图分类号:

R184

严珺, 尹文, 张侃. 新型冠状病毒（SARS-CoV-2）对血液安全的影响^*[J]. 临床输血与检验, 2020, 22(3): 232-235.

YAN Jun, YIN Wen, ZHANG Kan. Impact of SARS-CoV-2 on Blood Safety[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(3): 232-235.

参考文献

[1] Zhang C,Wang M. Origin time and epidemic dynamics of the2019 novel coronavirus[EB/OL]. (2020-01-25). [2020-02-29]. https://www.biorxiv.org/content/10.1101/2020.01.25.919688v2.
[2] World Health Organization. WHO MERS-CoV Global Summary and Assessment of Risk[EB/OL]. (2018-08-18). [2020-02-29]. https://www.who.int/csr/disease/coronavirus_infections/risk-assessment-august-2018.pdf?ua=1.
[3] Backer JA, Klinkenberg D, Wallinga J. The incubation period of2019-nCoV infections among travellers from Wuhan,China[EB/OL]].(2020-01-27).[2020-02-29].https://www.medrxiv.org/content/10.1101/2020.01.27.20018986v2.
[4] Chan JF-W,Yuan S,Kok K-H,et al.A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster[J]. Lancet. 2020; 395: 514-523.
[5] 高国静, 邱艳, 张评,等. 北京地区无偿献血人群中SARS流行病学调查[J]. 中国输血杂志, 2003, 16(4): 223-226.
[6] Schmidt M, Brixner V, Ruster B, et al.NAT screening of blood for severe acute respiratory syndrome coronavirus can potentially prevent transfusion associated transmissions[J]. Transfusion. 2004, 44(4): 470-475.
[7] The American Association of Blood Banks, TRANSFUSION August 2009 Supplement Fact Sheets Table of Contents[EB/OL]. (2009-08). [2020-02-29] http://www.aabb.org/tm/eid/Documents/150s.pdf.
[8] Corman VM, Albarrak AM, Omrani AS, et al.Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection[J]. Clin Infect Dis,2016, 62(4): 477-483.
[9] Kim SY, Park SJ, Cho SY, et al.Viral RNA in Blood as Indicator of Severe Outcome in Middle East Respiratory Syndrome Coronavirus Infection[J]. Emerg Infect Dis,2016, 22(10): 1813-1816.
[10] Huang C, Wang Y, Li X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet. 2020,395: 497-506.
[11] Wei-jie Guan,Zheng-yi Ni,Yu Hu,et al. Clinical characteristics of2019 novel coronavirus infection in China[EB/OL].(2020-02-09).[2020-02-29].https://www.medrxiv.org/content/10.1101/2020.02.06.20020974v1.
[12] World Health Organization. Maintaining a safe and adequate blood supply during pandemic influenza: Guidelines for Blood Transfusion Services [EB/OL]. (2011-07). [2020-02-29]. https://www.who.int/bloodsafety/publications/who_eht_11_03_en.pdf?ua=1.
[13] 国家卫生健康委办公厅,国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第七版)[EB/OL]. (2020-03-03).[2020-03-05].http://www.gov.cn/zhengce/zhengceku/2020-03/04/5486705/files/ae61004f930d47598711a0d4cbf874a9.pdf
[14] Food and Drug Administration. Important information for blood establishments regarding the novel coronavirus outbreak[EB/OL].(2020-02-04) .[2020-02-29].https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-information-blood-establishments-regarding-novel-coronavirus-outbreak.
[15] The American Association of Blood Banks,Update: Impact of 2019 Novel Coronavirus and Blood Safety [EB/OL].(2020-02-25) .[2020-02-29].http://www.aabb.org/advocacy/regulatorygovernment/Documents/Impact-of-2019-Novel-Coronavirus-on-Blood-Donation.pdf.
[16] 国家卫生健康委员会办公厅,中央军委后勤保障部卫生局.关于做好新型冠状病毒肺炎疫情期间血液安全供应保障工作的通知[EB/OL].(2020-02-10).[2020-02-29].http://www.nhc.gov.cn/yzygj/s7658/202002/4e2ca7554407485ba3f91b83f7332bdd.shtml.
[17] Eickmann M,Gravemann U,Handke W,et al.Inactivation of three emerging viruses - severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light[J]. Vox Sanguinis,2020.
[18] 魏静, 路志浩,宋奎良,等. 核黄素和紫外线光化学法处理血浆制品中中东呼吸综合征冠状病毒的灭活效果观察[J]. 临床输血与检验, 2018, 20(1): 99.
[19] Saá P,Proctor M,Foster G,et al.Investigational Testing for Zika Virus among U.S. Blood Donors[J]. N Engl J Med,2018, 378(19):1778-1788.

新型冠状病毒（SARS-CoV-2）对血液安全的影响^*

Impact of SARS-CoV-2 on Blood Safety

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	朱永明. 血液工作的总目标与当前的一些主要问题[J]. 临床输血与检验, 2021, 23(1): 6-10.
[2]	范亮峰, 陆琼, 姜跃琴, 王中英, 向东. 人血液经56℃孵育处理后溶血率及血型抗原抗体变化^*[J]. 临床输血与检验, 2021, 23(1): 54-60.
[3]	李萌, 赵玉伟, 李莹, 魏习薇, 谭茜茜, 傅雪梅. 无偿献血者健康检查标准的国内外比较^*[J]. 临床输血与检验, 2021, 23(1): 116-122.
[4]	陈庆恺, 何子毅. 输血传播疟疾与血液安全[J]. 临床输血与检验, 2021, 23(1): 122-126.
[5]	王世春, 阮潜瑛, 刁荣华, 喻荷莲, 戚超, 宋敏, 王珊, 姚春艳. COVID-19流行期间采供血工作特点及对策^*[J]. 临床输血与检验, 2020, 22(5): 454-457.
[6]	杨元铭, 刘姣, 赵真, 王蓉, 张少强, 王海燕. 新冠肺炎疫情期间输血科综合防控措施及效果评价[J]. 临床输血与检验, 2020, 22(5): 470-472.
[7]	杨俊鸿, 黄霞, 何涛, 李小红. 献血不良反应监测进展^*[J]. 临床输血与检验, 2020, 22(5): 556-560.
[8]	朱鑫方, 王苑, 杜丹心, 夏荣. 康复者恢复期血浆在病毒性疾病治疗中的研究进展[J]. 临床输血与检验, 2020, 22(4): 337-342.
[9]	王云, 赵长城, 谷妍, 姚余有, 刘杨, 岳莉, 石玉如, 查晓丹, 戚应杰. 80例新型冠状病毒感染肺炎患者相关血液检测指标分析[J]. 临床输血与检验, 2020, 22(4): 360-366.
[10]	李营, 张树超, 张少强, 程聪, 王海燕. 康复者血浆治疗新型冠状病毒肺炎疗效分析1例[J]. 临床输血与检验, 2020, 22(4): 366-370.
[11]	曾凡荣, 刘江, 杨光, 王小波, 张洁, 何玢, 朱利杰, 孙梦阳, 余寿杰. 淮南市新型冠状病毒感染病例实验室核酸检测结果分析[J]. 临床输血与检验, 2020, 22(4): 371-375.
[12]	杨俊鸿, 胡文杰, 杨丹蓉, 何涛, 黄霞. 新型冠状病毒肺炎疫情期间献血相关血管迷走神经反应预防措施及监测效果分析[J]. 临床输血与检验, 2020, 22(4): 376-379.
[13]	中国输血协会临床输血管理学委员会. 2019新型冠状病毒肺炎防控期间临床输血血型血清学实验室生物安全防护指南（第二版）^*[J]. 临床输血与检验, 2020, 22(3): 225-228.
[14]	李剑平, 李晓丰, 赵立哲, 王宏阳, 李伟伟, 林园, 刘景汉. 输血相关治疗应用于新冠病毒肺炎救治中的思考^*[J]. 临床输血与检验, 2020, 22(3): 228-232.
[15]	刘奇, 王世春, 姚春艳. 血浆置换在病毒性呼吸道传染病细胞因子风暴治疗中的作用^*[J]. 临床输血与检验, 2020, 22(3): 236-241.